William Creasman to Drug Administration Schedule
This is a "connection" page, showing publications William Creasman has written about Drug Administration Schedule.
Connection Strength
0.145
-
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5.
Score: 0.044
-
An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med. 1999 Jun-Aug; 44(4):186-92.
Score: 0.037
-
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
Score: 0.033
-
Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1985 Jun 15; 152(4):418-23.
Score: 0.014
-
A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Am J Obstet Gynecol. 1979 Nov 01; 135(5):647-50.
Score: 0.010
-
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
Score: 0.007